ArticleLipids in health and disease2025
MLN4924 inhibits macrophage foam cell formation by enhancing autophagy and regulating metabolic phenotype.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From Storage to Signaling: Lipid Droplet Lipolysis in Cholesterol Mobilization and Foam Cell Remodeling.Current atherosclerosis reports · 2026Review
- Upregulated FASN-mediated lipogenesis in senescent macrophages contributes to liver fibrosis progression.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMLN4924 is a novel small molecule inhibitor of neddylation. During clinical trials, it has demonstrated promising therapeutic efficacy in hematological malignancies, lung cancer, and colon cancer. MLN4924 possesses anti-inflammatory properties and promotes cardiomyocyte autophagy. Given that atherosclerosis is an inflammatory disease in which autophagy and cellular senescence are key factors, we hypothesize that MLN4924 may exert a regulatory effect on the progression of atherosclerosis, warranting further investigation. The formation of foam cells plays a critical role in the development of atherosclerosis.
methodsWe evaluated the effects of MLN4924 on the mRNA and protein expressions of scavenger receptor genes in macrophages and genes associated with the senescence-associated secretory phenotype (SASP). Oil Red O staining, Dil-ox-LDL uptake staining and cellular β-galactosidase staining were employed to assess the impacts of MLN4924 on the transformation of macrophages into foam cells and the senescence of macrophages. LC3 immunofluorescence staining, RT-qPCR and western blot were utilized to detect the regulatory effects of MLN4924 on macrophage autophagy. RNA sequencing (RNA-seq) and untargeted metabolomics analysis was carried out to evaluate the regulatory effects of MLN4924 on the transcriptome of macrophages and key metabolites.
resultsOur findings indicate that MLN4924 significantly downregulates the expressions of scavenger receptors such as CD36, SR-A1, SR-B1, and LOX-1, while upregulating genes associated with cholesterol efflux, including ABCA1 and ABCG1. Additionally, MLN4924 inhibits macrophage senescence and suppresses the expressions of SASP factors. The mechanism by which MLN4924 exerts these effects likely involves enhancing autophagy, thereby mitigating atherosclerotic progression. Furthermore, we conducted transcriptomic and metabolomic analyses to explore the effects of MLN4924 on macrophage transcriptome and metabolic phenotypes. Pathway enrichment analyses reveal significant enrichment of differentially expressed genes in the PI3K-AKT signaling pathway.
conclusionsWe confirmed that MLN4924 inhibits AKT phosphorylation, thereby suppressing its activation and further inhibits GSK-3β phosphorylation. Moreover, MLN4924 regulates the mRNA levels of multiple genes and modulates metabolite production. These findings demonstrate that MLN4924 could inhibit the formation of foam cells, justifying further in-depth research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.